New Treatments & Clinical Trials for Mantle Cell Lymphoma

Mantle cell lymphoma is a rare, aggressive B-cell lymphoma that typically affects people in their sixties. Treatment has improved dramatically over the past decade with newer targeted drugs called BTK inhibitors and drugs that restore normal cell death. Many people now achieve years of remission, though the disease often returns and requires further treatment.

What's actually going on in research

Trials are testing combinations of BTK inhibitors with other targeted drugs, CAR T-cell therapy that engineers immune cells to attack lymphoma, bispecific antibodies that connect cancer cells to immune cells, and novel drugs targeting BCL-2 and other survival pathways. Researchers are also studying maintenance strategies to extend remission and treatment sequences that maximize time without chemotherapy.

What to know before you search

Eligibility typically depends on number of prior treatments, recent chemotherapy or stem cell transplant, organ function, and sometimes specific genetic features of the lymphoma.

What types of trials are currently open

• Targeted therapy trials — Testing BTK inhibitors, BCL-2 inhibitors, or combinations of targeted drugs, often comparing new combinations against standard treatment.
• CAR T-cell trials — Studies of engineered immune cells for relapsed disease, or testing CAR T earlier in treatment before the disease becomes resistant.
• Bispecific antibody trials — Testing drugs that connect lymphoma cells to immune cells, given as infusions or subcutaneous injections.
• Maintenance trials — Testing whether continuing targeted therapy after remission extends the time before lymphoma returns.
• Minimal residual disease studies — Using sensitive tests to detect tiny amounts of remaining lymphoma and guide treatment decisions.